CHA Biotech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Chabiotech stores umbilical cord blood, conducts stem-cell research, and develops cell-based therapies, treatments that use living cells to address disease, while also providing anti-aging services and related consulting.
Its customers include individuals and healthcare institutions that use these biological storage and therapeutic services. Through its principal subsidiaries, the company also operates in pharmaceuticals, global contract development and manufacturing (CDMO, where a firm handles drug development and production on behalf of other companies), and international medical-network services. Chabiotech is listed on KOSDAQ, South Korea's tech and small-cap exchange.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates across multiple business lines through subsidiaries, spanning cord-blood banking, drug manufacturing services, and overseas medical networks under one consolidated group.
CHA Biotech in five facts
What does CHA Biotech do?
Chabiotech stores umbilical cord blood, conducts stem-cell research, and develops cell-based therapies, treatments that use living cells to address disease, while also providing anti-aging services and related consulting.
Where is CHA Biotech listed and in which sector?
CHA Biotech (Korean name: 차바이오텍) trades under KRX code 085660 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is CHA Biotech?
Its market capitalisation was US$531.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were CHA Biotech's latest annual revenue and operating profit?
For fiscal year 2025, CHA Biotech reported revenue of US$957.2M, an operating loss of US$36.8M and a net loss of US$110.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 21.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 16
- [Amended] DisclosureSep 30
- [Amended] DisclosureSep 28
- DisclosureSep 17
- DisclosureSep 16
- Report on large shareholdings (5% rule) (standard)Sep 14
- [Amended] DisclosureSep 10
- Report on large shareholdings (5% rule) (standard)Sep 3
- Early redemption of convertible bonds (incl. overseas CBs)
Chabiotech acquired the full outstanding US$301K face value of its 8th convertible bonds before maturity on 2026-08-18 for the same amount, following a bondholder's exercise of its put option, reducing outstanding face value to zero.
Capital raise · Aug 18 - Decision to acquire shares/equity in another company
CHA Biotech disclosed an acquisition of CHA Healthcare Co., Ltd., worth US$56.8M.
M&A · Aug 18 - [Amended] Decision to acquire shares/equity in another company
CHA Biotech updated the disclosed terms of an acquisition of CHA Healthcare Co., Ltd., now worth US$99.5M.
M&A · Jun 26 · 2 versions - Decision to redeem own exchangeable bonds earlyCapital raise · Jun 26
- Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Jun 26
- Decision to acquire shares/equity in another company
CHA Biotech disclosed an acquisition of Pium AI Future Healthcare New Technology Finance Investment Partnership, worth US$39M.
M&A · Jun 18 - Material event reportCapital raise · Mar 5
- Material event reportCapital raise · Mar 5
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
CHA Biotech reported consolidated results for FY2025: revenue of US$885M (+21.3% year on year), an operating loss of US$33.2M and a net loss of US$97.2M.
Earnings · Feb 27 - Material event reportCapital raise · Feb 13
- Material event report (CB call option holder designated)Capital raise · Feb 13
- Material event report (rights offering)Capital raise · Jan 16
- Material event report (rights offering)Capital raise · Jan 14